Sentynl Therapeutics, a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences and Fortress Biotech (FBIO), announced that the U.S. Food and Drug Administration has accepted for filing and Priority review Sentynl’s New Drug Application for CUTX-101, the product candidate for the treatment of Menkes disease. Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A. Recent estimates suggest a prevalence of 1 in 34,810 to as high as 1 in 8,664 live male births.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBIO:
- Biotech Alert: Searches spiking for these stocks today
- Fortress Biotech price target raised to $15 from $13 at Roth MKM
- Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners
- Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright
- Fortress Biotech’s Q3 2024 Earnings and FDA Milestone